Review decision date: February 2014
This guideline should not be updated at this time. For further information, please refer to the surveillance review decision.
Next review date: TBC
The Medicines and Healthcare Products Regulatory Agency (MHRA) has strengthened its warnings on the use of valproate in women of childbearing potential. NICE is currently assessing the impact of this on its epilepsy guideline (CG137). In the meantime, healthcare professionals are advised to use the guideline in conjunction with the latest MHRA advice.
This clinical guideline updates and replaces NICE guideline CG20 (published in 2004). It also updates and replaces NICE technology appraisal 76 (published in 2004) and NICE technology appraisal 79 (published in 2004).
It offers evidence-based advice on the care and treatment of children, young people and adults with epilepsy. New recommendations have been added for the pharmacological treatment of people with epilepsy, including the use of ketogenic diet.
A footnote has been added to the NICE guideline (recommendation 126.96.36.199) and full guideline (recommendation 81) highlighting new advice issued by the MHRA about oral anti-epileptic drugs (AEDs) and switching between different manufacturers’ products of a particular drug. See the MHRA advice for more information. Also see the medicines evidence commentary, which helps to contextualise the changes to the guideline.